EphA2 on Urinary Extracellular Vesicles As a Novel Biomarker for Bladder Cancer Diagnosis and Its Effect on the Invasiveness of Bladder Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2022 Jul 6

PMID 35794239

Authors

Eisuke Tomiyama

Kazutoshi Fujita

Kyosuke Matsuzaki

Ryohei Narumi

Akinaru Yamamoto

Toshihiro Uemura

Gaku Yamamichi

Yoko Koh

Makoto Matsushita

Yujiro Hayashi

Mamoru Hashimoto

Eri Banno

Taigo Kato

Koji Hatano

Atsunari Kawashima

Motohide Uemura

Ryo Ukekawa

Tetsuya Takao

Shingo Takada

Hirotsugu Uemura

Jun Adachi

Takeshi Tomonaga

Norio Nonomura

Affiliations

Soon will be listed here.

Abstract

Background: Urinary extracellular vesicles (uEVs) secreted from bladder cancer contain cancer-specific proteins that are potential diagnostic biomarkers. We identified and evaluated a uEV-based protein biomarker for bladder cancer diagnosis and analysed its functions.

Methods: Biomarker candidates, selected by shotgun proteomics, were validated using targeted proteomics of uEVs obtained from 49 patients with and 48 individuals without bladder cancer, including patients with non-malignant haematuria. We developed an enzyme-linked immunosorbent assay (ELISA) for quantifying the uEV protein biomarker without ultracentrifugation and evaluated urine samples from 36 patients with and 36 patients without bladder cancer.

Results: Thirteen membrane proteins were significantly upregulated in the uEVs from patients with bladder cancer in shotgun proteomics. Among them, eight proteins were validated by target proteomics, and Ephrin type-A receptor 2 (EphA2) was the only protein significantly upregulated in the uEVs of patients with bladder cancer, compared with that of patients with non-malignant haematuria. The EV-EphA2-CD9 ELISA demonstrated good diagnostic performance (sensitivity: 61.1%, specificity: 97.2%). We showed that EphA2 promotes proliferation, invasion and migration and EV-EphA2 promotes the invasion and migration of bladder cancer cells.

Conclusions: We established EV-EphA2-CD9 ELISA for uEV-EphA2 detection for the non-invasive early clinical diagnosis of bladder cancer.

Citing Articles

Prospect of extracellular vesicles in tumor immunotherapy.

Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.

PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.

Sam-Sam Association Between EphA2 and SASH1: In Silico Studies of Cancer-Linked Mutations.

Vincenzi M, Mercurio F, Autiero I, Leone M Molecules. 2025; 30(3).

PMID: 39942820 PMC: 11820823. DOI: 10.3390/molecules30030718.

Extracellular Vesicles and Their Applications in Tumor Diagnostics and Immunotherapy.

Strum S, Evdokimova V, Radvanyi L, Spreafico A Cells. 2024; 13(23.

PMID: 39682778 PMC: 11639792. DOI: 10.3390/cells13232031.

Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance.

Zhang Y, Shi R, Meng R, Lin S, Zheng M World J Gastrointest Oncol. 2024; 16(9):3781-3797.

PMID: 39350985 PMC: 11438782. DOI: 10.4251/wjgo.v16.i9.3781.

A Panorama of Extracellular Vesicle Applications: From Biomarker Detection to Therapeutics.

Das S, Lyon C, Hu T ACS Nano. 2024; 18(14):9784-9797.

PMID: 38471757 PMC: 11008359. DOI: 10.1021/acsnano.4c00666.

References

Babjuk M . Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?. Eur Urol. 2016; 71(1):109-110. DOI: 10.1016/j.eururo.2016.06.040. View

Yoshida T, Kates M, Fujita K, Bivalacqua T, McConkey D . Predictive biomarkers for drug response in bladder cancer. Int J Urol. 2019; 26(11):1044-1053. DOI: 10.1111/iju.14082. View

Lotan Y, Roehrborn C . Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003; 61(1):109-18; discussion 118. DOI: 10.1016/s0090-4295(02)02136-2. View

Schmitz-Drager B, Droller M, Lokeshwar V, Lotan Y, Hudson M, van Rhijn B . Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2014; 94(1):1-24. DOI: 10.1159/000369357. View

Fujita K, Nonomura N . Urinary biomarkers of prostate cancer. Int J Urol. 2018; 25(9):770-779. DOI: 10.1111/iju.13734. View

Linxweiler J, Junker K . Extracellular vesicles in urological malignancies: an update. Nat Rev Urol. 2019; 17(1):11-27. DOI: 10.1038/s41585-019-0261-8. View

Matsuzaki K, Fujita K, Jingushi K, Kawashima A, Ujike T, Nagahara A . MiR-21-5p in urinary extracellular vesicles is a novel biomarker of urothelial carcinoma. Oncotarget. 2017; 8(15):24668-24678. PMC: 5421878. DOI: 10.18632/oncotarget.14969. View

Tomiyama E, Matsuzaki K, Fujita K, Shiromizu T, Narumi R, Jingushi K . Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers. Cancer Sci. 2021; 112(5):2033-2045. PMC: 8088963. DOI: 10.1111/cas.14881. View

Lee J, McKinney K, Pavlopoulos A, Niu M, Kang J, Oh J . Altered Proteome of Extracellular Vesicles Derived from Bladder Cancer Patients Urine. Mol Cells. 2018; 41(3):179-187. PMC: 5881091. DOI: 10.14348/molcells.2018.2110. View

10.

Smalley D, Sheman N, Nelson K, Theodorescu D . Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res. 2008; 7(5):2088-96. DOI: 10.1021/pr700775x. View

11.

Chen C, Lai Y, Tang P, Chien K, Yu J, Tsai C . Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res. 2012; 11(12):5611-29. DOI: 10.1021/pr3008732. View

12.

Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A . Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016; 12:105-117. PMC: 5078592. DOI: 10.1016/j.ebiom.2016.08.036. View

13.

Tomiyama E, Fujita K, Hashimoto M, Miyamoto H, Netto G, Nonomura N . Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma. Int J Urol. 2021; 29(1):89-90. DOI: 10.1111/iju.14689. View

14.

Ran F, Hsu P, Wright J, Agarwala V, Scott D, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11):2281-2308. PMC: 3969860. DOI: 10.1038/nprot.2013.143. View

15.

Wei Q, Wei L, Zhang J, Li Z, Feng H, Ren L . EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer. Mol Med Rep. 2020; 22(4):2941-2947. PMC: 7466360. DOI: 10.3892/mmr.2020.11384. View

16.

E F, Zhang H, Yin W, Wang C, Liu Y, Li Y . CPEB3 deficiency in mice affect ovarian follicle development and causes premature ovarian insufficiency. Cell Death Dis. 2021; 13(1):21. PMC: 8688431. DOI: 10.1038/s41419-021-04374-4. View

17.

Pasquale E . Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008; 133(1):38-52. DOI: 10.1016/j.cell.2008.03.011. View

18.

Wilson K, Shiuan E, Brantley-Sieders D . Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021; 40(14):2483-2495. PMC: 8035212. DOI: 10.1038/s41388-021-01714-8. View

19.

Dunne P, Dasgupta S, Blayney J, McArt D, Redmond K, Weir J . EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clin Cancer Res. 2015; 22(1):230-242. PMC: 4694030. DOI: 10.1158/1078-0432.CCR-15-0603. View

20.

Brannan J, Dong W, Prudkin L, Behrens C, Lotan R, Bekele B . Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009; 15(13):4423-30. DOI: 10.1158/1078-0432.CCR-09-0473. View